Irish medical technology firm Medtronic has agreed to spend around $203m to acquire US-based medical device firms Aptus Endosystems and CardioInsight Technologies.
Aptus is involved in developing advanced technology for endovascular aneurysm repair (EVAR) and thoracic endovascular aneurysm repair (TEVAR).
Medtronic cardiac and vascular group aortic business general manager Daveen Chopra said: "The Heli-FX and Heli-FX Thoracic EndoAnchor systems strongly align with our strategy to invest in treatments that address complex aortic disease with a vision to treat disease of the entire aorta."
Aptus produces Heli-FX and Heli-FX Thoracic EndoAnchor systems that feature an endovascular deployed anchor designed to attach different aortic endografts to the native vessel wall.
Both systems, which obtained CE mark and FDA approval, can be used with a wide range of commercially available stent grafts, including Medtronic’s Endurant and Valiant stent graft systems.
Under the deal, Medtronic will also distribute Aptus’ TourGuide Steerable Sheath, a device that allows to deliver peripheral vascular products to the most challenging anatomy, in the US and Europe.
Medtronic will include CardioInsight into its atrial fibrillation solutions business of cardiac rhythm and heart failure division.
CardioInsight produces Ecvue system that is designed to non-invasively generate images of the electrical activity of the heart by combining body surface electrical data with 3-dimensional (3-D) anatomical data.
Medtronic AF Solutions business general manager and vice-president Reggie Groves said: "CardioInsight will broaden and enhance the existing AF Solutions program at Medtronic, and will provide meaningful clinical and economic solutions for patients, hospitals, physicians and payers."
Image: Medtronic operational headquarters, Minneapolis. Photo: courtesy of Medtronic, Inc.